Last updated 2026-07-20
Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Rounds' value
—
total disclosed, rounds participated
Stages
—
About
HealthCare Royalty (HCRx) is a leading royalty acquisition company founded in 2006 that invests in commercial-stage and near-commercial-stage biopharmaceutical assets. It acquires and manages royalty streams from innovative therapeutics targeting unmet medical needs. HCRx has committed over $7 billion in capital across more than 110 biopharmaceutical products and manages approximately $3 billion in assets. In July 2025, KKR acquired a majority ownership stake in HCRx.
Portfolio
No portfolio companies in this dataset yet.
Investment activity
Portfolio by sector
Health Tech & Life Sciences1
Q&A
- What is HealthCare Royalty Partners' primary investment focus?
- HealthCare Royalty Partners focuses on the Health Tech & Life Sciences sector, with one portfolio company, RedHill Biopharma, in this area.
- Can you name a notable portfolio company of HealthCare Royalty Partners?
- RedHill Biopharma, a company developing proprietary drugs for gastrointestinal and infectious diseases, is a portfolio company of HealthCare Royalty Partners.
- What type of funding rounds does HealthCare Royalty Partners typically participate in?
- HealthCare Royalty Partners has participated in Debt Financing rounds.
- When was HealthCare Royalty Partners' most recent investment activity?
- HealthCare Royalty Partners' most recent investment activity occurred in February 2020.
- What is the typical investment range for HealthCare Royalty Partners?
- HealthCare Royalty Partners' investment range is between $115M and $115M.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2006 |
|---|